The purpose of this study was to evaluate the influence of bone marrow-mesenchymal stem cells (BM-MSC) and exogenously added cytokines on the proliferation, primitive cell subpopulation maintenance (including the c-kit+ marker) and clonogenic capacity of hematopoietic stem cells (HSC). BM-MSC were collected from volunteer donors, isolated and characterized. Umbilical cord blood (UCB) samples were collected from healthy full-term deliveries. UCB-CD34+ cells were cultured in the presence or absence of BM-MSC and/or cytokines for 3 and 7 days. CD34+ cell proliferation was evaluated using the CSFE method and cell phenotype was determined by CD34, c-kit, CD33, CD38, HLA-DR, cyCD22 and cyCD3 detection. Cell clonogenic ability was also assessed. Exogenously added SCF, TPO and FLT3L increased Vol. 18. No. 1. 2013 CELL. MOL. BIOL. LETT. 12 CD34+ cell proliferation in the presence or absence of BM-MSC, but with concomitant cell differentiation. Without any added cytokines, BM-MSC are able to increase the percentage of primitive progenitors as evaluated by c-kit expression and CFU-GEMM increase. Interestingly, this latter effect was dependent on both cell-cell interactions and secreted factors. A 7-day co-culture period will be optimal for obtaining an increased primitive HSC level. Including c-kit as a marker for primitive phenotype evaluation has shown the relevance of BM-MSC and their secreted factors on UCB-HSC stemness function. This effect could be dissociated from that of the addition of exogenous cytokines, which induced cellular differentiation instead.
INTRODUCTION
Experimental evidence from the last two decades has established that hematopoietic stem cells (HSC) from umbilical cord blood (UCB) can be used as a cell source for treatments for hematopoietic system-associated diseases [1] . However, the low numbers of hematopoietic progenitors present in UCB remains a drawback for their clinical application and further biological studies. Therefore, researchers have designed various strategies and cytokine cocktails for in vitro HSC expansion to ensure an adequate number of cells for transplantation [2, 3] . In particular, cytokines that are presumed to promote extensive cell self-renewal and to limit apoptosis levels have been used, such as stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt-3L) and thrombopoietin (TPO) [4, 5] . UCB-HSC expansion protocols have led to improved results in clinical trials, with reduced neutrophil and platelet count time recovery in patients who received transplanted cells [6] . However, other studies have also revealed changes in HSC biological features after in vitro cytokine-driven HSC expansion. In fact, in vitro-expanded hematopoietic progenitors have reduced engraftment capacity [7] , altered VLA-4 and VLA-5 expression [8] , increased Fas ligand (CD95) expression [9] , downregulation of the anti-apoptotic protein Bcl-2 [10] and increased caspase activation [11] . It is likely that the observed changes in HSC after in vitro expansion are attributable to the lack of a suitable microenvironment that maintains their biological properties, as per Schofield's "niche hypothesis" [12] . Several studies have supported this concept and have extended it to show that the HSC niche in the bone marrow (BM) consists of several cell types, including fibroblasts, pericytes, endothelial cells, osteoblasts and mesenchymal stem cells (MSC) along with extracellular matrix glycoproteins [13, 14] . In particular, BM-MSC are important regulators of the hematopoietic microenvironment because they have the capacity to differentiate into specialized stem cells. They also contribute to provide suitable support for hematopoiesis in this milieu by synthesizing a complex network of cytokines, adhesion molecules and extracellular matrix proteins, regulating HSC survival, proliferation, growth and differentiation [15, 16] . BM-MSC have thus been included in HSC expansion strategies and niche studies for maintaining HSC biological characteristics ex vivo. There are two important issues to consider: if BM-MSC-secreted cytokines are sufficient to maintain HSC characteristics or if exogenous cytokines are needed to induce cell expansion and undifferentiated phenotype maintenance. The effect of BM-MSC on HSC proliferation [17] and maintenance has been studied in populations that are considered primitive due to their CD34+CD38-phenotype or slight modifications thereof [16, [18] [19] [20] . Flores-Guzman et al. showed that BM-MSC play a key role in primitive cell phenotype maintenance in CD34+CD38-Lin-populations. Others have demonstrated that BM-MSC support HSC expansion or self-renewal in CD133+, CD34+CD38-CD133+ or CD34+CD38-cells [6, 18, 19, 21] . It is believed that CD34+CD38-is the most primitive phenotype since it is associated with human long-term cultureinitiating cell (LTC-IC) production and contains SCID-human-repopulating and NOD-SCID-repopulating cells [22] [23] [24] . However, other studies have shown that the CD34+CD38+ population is also capable of repopulating immunodeficient mice [25] [26] [27] . Therefore, the presence or absence of CD38 is not enough to define HSC as primitive. In clinical diagnosis, it is not enough to consider a patient sample as having a high content of primitive cells by detecting only CD34 or CD38 antigens [28] . Therefore, it is important to evaluate other antigens or their combinations to establish the HSC primitive phenotype and stemness function. The CD117 or c-kit, characterized by Yarden et al. in 1987 [29] , is expressed in hematopoietic cells and also in several non-hematopoietic tissues and tumors [30] . Together with CD33 and HLA-DR, it has been used for leukemia diagnosis. The c-kit antigen is specifically expressed in BM in the progenitor compartment. Upon differentiation, its expression is downregulated, other than in the mast cells [28, 29] . Up to 70% of CD34+ BM progenitor cells co-express c-kit [30, 31] and the CD34+c-kit+ subpopulation contains the cells with the highest clonogenic activity (CFU-GM, CFU-mix and BFU-E) [32, 33] . Interestingly, human clinical studies have shown that the primitive hematopoietic progenitor cells, including the burst-forming unit megakaryocyte, the high proliferative potential colony-forming cell and the long-term BM culture-initiating cell, are contained within the CD34+c-kit+HLA-DR subpopulation, indicating that human stem cells are c-kit positive [34] . It has also been shown that changes in c-kit and HLA-DR antigen expression on the CD34+ cell population can be indicative of HSC primitive progenitor characteristics or commitment to the monocytic lineage [28, 35] . Consequently, short-term (3-and 7-day) UCB-HSC cultures were established to study the effect of BM-MSC on secreted or exogenously added cytokines over HSC proliferation, myeloid or lymphoid primitive-associated progenitor phenotypes and clonogenic capacity. Our results showed that in the absence of exogenously added cytokines, BM-MSC induce slight CD34+ proliferation, promoting primitive progenitor maintenance with higher multi-lineage potential and increased CD34 and c-kit expression.
MATERIALS AND METHODS
Mesenchymal stem cell isolation from bone marrow BM aspirates were collected in a sterile tube containing ethylene diaminetetraacetic acid anticoagulant (EDTA) from the iliac crest of healthy donors aged 19-65 after they had signed an informed consent form and approval had been given by the ethical committee of Hospital Universitario San Ignacio. Mononuclear cells were isolated by Ficoll density gradient centrifugation (Histopaque d = 1.077 g/cm 3 , Sigma-Aldrich, USA) and cells were plated at a density of 10 6 cells/cm 2 in IMDM Glutamax-I (GIBCO, Invitrogen) supplemented with 1% sodium pyruvate (GIBCO, Invitrogen), 1% MEM nonessential amino acid solution 100X (Sigma-Aldrich, USA) and 10% fetal calf serum (FCS). After obtaining 90% cell confluence, BM-MSC were detached by treatment with 0.25% Trypsin and 1 mM EDTA (GIBCO, Invitrogen) and replated at about 1.5 x 10 5 cells/ml for all experiments. MSC were used for the various experiments in passages 3-5.
Mesenchymal stem cell immunophenotyping
After the 3 rd passage, adherent cells were trypsinized and labeled with combinations of monoclonal antibodies (CD105/CD73/CD45/CD34; CD44/CD90/CD45/CD13; and HLA-I/HLA-DR/CD45/CD34) in four color stainings per group using fluorescein isothiocyanate, phycoerythrinperidinin chlorophyll protein, phycoerythrinperidinin Cy5.5 and allophycocyanin. Data were acquired using a FACSCalibur flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA). CellQUEST PRO software, FlowJo and Paint-a-Gate (Becton Dickinson Biosciences) were used for data analysis.
Mesenchymal stem cell in vitro differentiation
After the 3 rd passage, the osteogenic, adipogenic and chondrogenic differentiation capacities were qualitatively determined using specific staining and optical microscopy examination. MSC were replated at 2x10 4 cells/1.5 cm 2 and cultured to reach 90% confluence in IMDM with culture medium to induce osteogenic [36, 37] , adipogenic [36, 38] and chondrogenic differentiation [36, 39] .
CD34+ cell isolation from human umbilical cord blood UCB samples from normal full-term deliveries were collected after obtaining informed consent in accordance with the guidelines approved by the ethics committees of the Hospital Materno-Infantil and Hospital Universitario San Ignacio. Mononuclear cells were isolated by Ficoll density gradient centrifugation (Histopaque d = 1.077g/cm 3 , Sigma-Aldrich, USA) and CD34+ cells were enriched using a previously described magnetic-activated cell-sorting (MACS) CD34 isolation kit (MiltenyiBiotec, Auburn, CA, USA) [40] . Cell purity was evaluated by flow cytometry using allophycocyanin anti-CD34 (Clone 8G12, BD Biosciences). The sample purity was above 87%. Cell viability was determined using trypan blue dye. The results were greater than 95% in all trials.
CD34+ cell divisions by carboxyfluorescein diacetate succinimidyl ester labeling
After isolation, UCB-CD34+ cells were labeled for 7 min at room temperature and 3 min at 37ºC with 5 μM carboxyfluorescein diacetate succinimidyl ester (CFSE; CellTrace CFSE Cell Proliferation Kit, Invitrogen) in 0.1% BSAsupplemented PBS. CFSE-labeled cells were suspended in RPMI (Invitrogen Corporation, Carlsbad, CA, USA) with 10% FCS for 5 min in ice and washed three times with PBS for 7 min at 400 x g and 20ºC. CFSE labeling was confirmed using fluorescence microscopy. A fraction of the CD34 cells were FCS deprived for 48 h (synchronized cells) to establish non-proliferating cells (the highest CFSE mean fluorescence intensity).
Culturing umbilical cord blood-CD34+CFSE+ cells with bone marrowmesenchymal stem cells and/or cytokines
Third passage confluent and characterized BM-MSC were used as the UCB-CD34+ feeder layer. The CD34+CFSE+ cells were cultured under three experimental conditions. i) 10 5 CD34+CFSE+ cells were plated in direct contact with confluent BM-MSC feeder cells in 24-well plates in standard medium (RPMI with vitamins) in the presence of 50 ng/ml stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt-3L) and thrombopoietin (TPO). These were the HMC culture conditions. ii) 10 5 CD34+CFSE+ cells were plated in direct contact with confluent BM-MSC feeder cells in 24-well plates in standard medium (RPMI with vitamins) without cytokines. These were the HM culture conditions. iii) 10 5 CD34+CFSE+ cells were plated in the presence of SCF, Flt-3L and TPO without BM-MSC. These were the HC culture conditions. Cultures were maintained in a humidified atmosphere at 37ºC for 3 and 7 days.
Umbilical cord blood-CD34+ immunophenotype evaluation after culture
All the cells were harvested by trypsin treatment after 3 and 7 days of co-culture, washed in PBS and stained with monoclonal antibodies in the four color stainings. The antigens were detected by flow cytometry according to the availability of fluorochromes (CD34/c-kit/CD33 or CD38/HLA-DR and CD34/cyCD22/cyCD3/HLA-DR). Reliable discrimination between BM-MSC and UCB-CD34+ cells was possible using their different forward scatter and side scatter signals and the high fluorescence of the CFSE-labeled hematopoietic cells (detected in FL1). Dead cells were excluded during acquisition (gate: intermediate forward scatter and low side scatter) and result analysis (FlowJo and Paint-A-Gate software to exclude the remaining dead cells; Supplementary Fig. 1 at http://dx.doi.org/ 10.2478/s11658-012-0036-1).
Umbilical cord blood-CD34+ cell clonogenic capacity After co-culture for 3 and 7 days, the UCB-CD34+ cells were separated by negative selection using an antibody against BM-MSC (CD105 Microbeads, 120-000-316 MACS, MiltenyiBiotec). Cultivated cells (0.5-1x10 3 /1.1 ml) were then cultured for 15 days in HSC-CFU complete with EPO medium (130-091-278. MiltenyiBiotec). Hematopoietic colonies were quantified with inverted microscopy and morphologically characterized with cytospin and Wright's staining, using the following colony criteria (www.stemcell.com): i) Colony-forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM) -granulocytes, erythrocytes and monocytes having at least 500 cells; ii) Burst-forming unit erythroids (BFU-E) and colony-forming unit-erythroids (CFU-E) -erythroblasts respectively having at least 200 and 10-200 cells; iii) Colony-forming unit-granulocyte macrophage (CFU-GM) -granulocytes and monocytes having at least 40 cells. In some experiments, UCB-CD34+ cells were cultured with BM-MSC supernatants obtained from fresh cultures (fresh supernatant, FS) or from supernatants frozen for 3 days at -70ºC (frozen supernatant, FRS). After 3 days, UCB-CD34 cells were cultured in HSC-CFU complete with EPO medium and colonies were counted as described previously.
Statistical analysis
The data were analyzed with Friedman's test or Kruskall Wallis method using SPSS v16.0 and GraphPad Prism 5.0 for graphics. Results were considered statistically significant when p < 0.05.
RESULTS

BM-MSC phenotype and multi-lineage differentiation
Following the recommendations of the International Society of Cellular Therapy, BM-MSC were morphologically (Fig. 1A-B) and immunophenotypically (Fig. 2) characterized. BM-MSC were negative for CD34 and CD45 and positive for CD105, CD90, CD73, CD13 and CD44, as previously described by other authors [41, 42] . Supplementary Table 1 at http://dx.doi.org/ 10.2478/s11658-012-0036-1 shows the percentage of positive cells for MSC antigens. Differentiation potential was evidenced in osteogenic, adipogenic and chondrogenic media ( Fig.  1C-E) , confirming MSC identity. All of the experiments were reproduced with samples from different patients to avoid variations between samples.
UCB-CD34+ cell proliferation in BM-MSC co-cultures
The BM repopulating efficiency of UCB-CD34+ cells in a transplant setting depends in part on the number of transplanted cells [1] . Short-term UCB-CD34+ co-cultures were performed under different conditions with or without BM-MSC Fig. 1 . Determining BM-MSC morphology and differentiation potential. A -BM-MSC showed a colony with fibroblast-like morphology after 15 days' culture (Olympus CK2, magnification x10. Scale bar: 100 μm). B -BM-MSC showed a fibroblast-like morphology after 15 days' culture (Olympus CK2, magnification 5x. Scale bar: 100 μm). C -BM-MSC showed osteogenic differentiation with increased ALP expression (alkaline phosphatase stain, Olympus CK2, magnification x10. Scale bar: 100 μm). D -Adipogenic differentiation showed a lipid-rich vacuole (Oil Red O stain, Olympus CK2, magnification x20. Scale bar: 50 μm). E -For chondrocyte differentiation, sulphated proteoglycan accumulations and extensive matrix were evident (Safranin O stain, Olympus Ck2, magnification x5. Scale bar: 100 μm). Photographs were taken with a Sony Cybershot DSC-W7digital camera and colors corrected after acquisition with Adobe Photoshop and BioImagenXD software.
or cytokines (HMC, HC and HM conditions) to explore UCB-CD34+ proliferation and cytokine contribution to growth (see the Materials and Methods section). After 3 and 7 days, UCB-CD34+ cells cultured in the presence of recombinant cytokines (SCF, Flt-3L, TPO) with or without BM-MSC (HMC and HC conditions) significantly increased the total UCB-CD34+ numbers and the percentage of cells with several cell divisions (Fig. 3B, C , F and G) compared to arrested cells (Fig. 3A) or HM setting (Fig. 3D-E) . The percentage of cells with only one cell division (P1) was higher under HM conditions than under HMC or HC conditions in the two periods studied. After 3 days under HM conditions, there were 95% cells in P1 compared to 70% and 60% for HMC and HC, respectively (p < 0.05; Fig. 3H) . A similar situation was observed after 7 days, with CD34+ cells undergoing 3 to 4 cell cycles under HMC and HC conditions, while most cells (about 85%) under HM conditions were still in the first round of cell division. BM-MSC do not induce changes in the CD34+ cell proliferation (Fig. 3D, E ) and the addition of exogenous cytokines is crucial to increase cell numbers. 
Extended (7-day) BM-MSC and UCB-CD34+ co-culturing maintained primitive progenitor percentage
Although the number of CD34+ cells from UCB is critical when considering clinical applications, maintaining an undifferentiated phenotype is also of great relevance. Several studies have shown that cell proliferation is closely related to the state of cell differentiation [43] [44] [45] . UCB-CD34+ cells were plated under each culture condition and the expression of the antigens CD34, c-kit, CD33, CD38, cyCD22, cyCD3 and HLA-DR was analyzed to assess their differentiation state. After 3 days, no significant differences (p > 0.05) in the percentages of CD34+CD38-, CD34+CD38+ or CD34+CD38+c-kit+ cells were observed under the different conditions. After 7 days, the HM conditions had a higher percentage of CD34+CD38-cells (6.5% vs. around 1% in the other two conditions, p < 0.05) and CD34+CD38+c-kit+ cells (92.4% vs. 47% in HMC and 23% in HC, p < 0.05; Fig. 4 ). This increase was mainly due to a reduction in a much more differentiated population expressing the myeloid marker CD33 (CD34+CD38+CD33+). Although the CD34+CD38-subpopulation was found within c-kit+ cells (Fig. 5D) , it is unclear whether the CD34+CD38-c-kit+ subpopulation has the same functional capabilities as the "classic" primitive CD34+CD38-phenotype. Interestingly, the CD34 and c-kit mean fluorescence intensity (MFI) was different under the three different conditions. After 3 days, the CD34+ MFI was lower (p < 0.05) under the HM conditions than under the conditions with cytokines (HMC and HC; Supplementary Table 2) . After 7 days, the situation reversed, with the HM conditions having the highest CD34+ MFI. A very similar situation was found with the c-kit MFI, with cells expressing a higher c-kit level under HM conditions after 7 days (p < 0.05; Fig. 6, Supplementary  Table 2 ). No changes were detected in the HLA-DR antigen, and lymphoid antigens were not detected in the co-culture systems used here after 3 or 7 days (data not shown). Without exogenous cytokines, BM-MSC influences HSC primitive phenotype maintenance, as may be observed after 3 days of co-culture (increase in CD34+CD38-and a decrease in CD34+CD38+CD33+). After 7 days, additional differences in the subpopulations were observed, with an important increase in the CD34+CD38-c-kit+ and CD34+CD38+c-kit+ populations. Under these conditions, the CD34 and c-kit MFI are higher (Fig. 6) . In terms of HSC (CD34+) primitive phenotype (CD38-, CD38+c-kit+ or CD33-) maintenance, it is clear that BM-MSC exerts a supportive effect that is recognizable after 7 days of co-culture.
BM-MSC without exogenous cytokines increased UCB-CD34+ clonogenic capacity
The differentiation potential of UCB-CD34+ cells into hematopoietic lineages was also evaluated. It was found that UCB-CD34+ cells isolated from the HM conditions showed a higher absolute count and percentage of CFU-GEMM than the other culture conditions. After 3 days, the HM conditions yielded 18 colonies of CFU-GEMM per 10 3 CD34+ cells (60%) compared to 5 colonies (14%) and 7 colonies (20%) under HMC and HC conditions, respectively (Fig. 7A, B) . Likewise, after 7 days under the HM conditions, an increased number of CFU-GEMM colonies was observed compared to the situation with the other two conditions (15 vs. 1 and 2 per 10 3 CD34+ cells; Fig. 7C, D) . Cytospins were performed on all of the colonies and it was found that CFU-GEMM colonies were indeed enriched in cells having immature morphology with basophilic and agranular cytoplasm and the presence of a low condensed nucleus having 2 or 3 nucleoli (Fig. 8A, B) , whereas the more committed colonies consisted of cells with the expected morphology. Erythroid progenitor colonies (BFU-E, CFU-E) had cells with an acidophilic cytoplasm and nucleus with condensed chromatin (Fig. 8C-F) . Granulocytic colonies (CFU-G) had abundant granules in their cytoplasm and monocytic colonies (CFU-M) had a semi-lobed nucleus with basophilic cytoplasm (Fig. 8G-I) . Again, BM-MSC (HM conditions) are able to induce not only higher percentages of CFU-GEMM but also a higher number of colonies compared to other culture conditions. UCB-CD34+ clonogenic assays were performed after BM-MSC co-culture or after adding fresh (FS) or frozen (FRS) BM-MSC culture supernatants. It was revealed that cells in direct contact (DC) under the HM conditions had a higher absolute count (18 colonies per 10 3 CD34+ cells, 60%) of CFU-GEMM colonies compared to hematopoietic cells in culture with supernatants (FS or FRS; p < 0.05; Fig. 9A ). However, it should be noted that 10 colonies (28%) of CFU-GEMM were observed when UCB-CD34+ were cultured with FS, suggesting that BM-MSC-secreted cytokines may also promote colony growth (Fig. 9A, B) . No CFU-GEMM colonies were observed when determining UCB-CD34+ clonogenic capacity after culturing with FRS; only colonies with committed lineages were detected (Fig. 9A-E ). These results demonstrate that cell contact in short-term culture UCB-CD34+ with BM-MSC can play an important role in the maintenance of primitive hematopoietic populations retaining their clonogenic ability. 
DISCUSSION
Different strategies have been designed for UCB-HSC ex vivo expansion. Several studies have shown that some cytokines can increase CD34+ cell number several-fold [46] [47] [48] [49] [50] [51] [52] . Clinical trials using pre-expanded UCB-CD34+ cells have shown that this is a safe and efficient procedure and that it does not increase the percentage of patients who develop graft-versus-host disease (GVHD) [53] . However, this procedure is expensive and the most commonly used cytokine concentrations (in the ng/ml range) do not correspond to the concentrations detected in vivo in the BM microenvironment (in the pg/ml range), which could alter the "quality" of the primitive progenitors responsible for long-term BM reconstitution [54] . The use of mesenchymal stem cells has also led to optimizing UCB-CD34+ cell expansion [54] . More recently, it has been shown that co-culturing UCB-HSC and mesenchymal cells (in the absence of cytokines) has stimulated the expansion of more primitive hematopoietic progenitors (CD34+CD38-or CD133+CD38-) [18] . This study aimed to evaluate the effect of BM-MSC on some biological characteristics of UCB-HSC, in the absence of high levels (ng/ml) of exogenous added cytokines, in a model much closer (only concerning in situ-produced cytokines) to what might be occurring in vivo. This is in agreement with several cytokine-free UCB-CD34+ expansion protocols that have been shown to be efficient [55, 56] . BM-MSC-secreted cytokines should have had synergistic effects with the added cytokines. Nevertheless, this study has shown that UCB-CD34+ cells expanded with exogenous cytokines in the presence (HMC) or absence (HC) of BM-MSC cells proliferate to the same extent (Fig. 3) . This was an unexpected result, since it had previously been shown that BM-MSC express SCF, TPO, Flt-3L, leukemia inhibition factor (LIF), IL-11 and IL-6 at the mRNA level [21] . Additionally, it is important to note that the paracrine effect of MSC could be dependent on the donor [57] and the culture conditions (e.g., type of culture medium) [58] . An extra supply of growth factors (SCF, Flt-3L and TPO) is definitely required for UCB-CD34+ expansion. Andrade et al. showed that UCB-CD34+ cells and BM-MSC co-cultured using the same cytokines tested here (SCF, Flt-3L and TPO) resulted in a 17-fold CD34+ cell expansion [46] , thereby partly agreeing with our results. Nevertheless in this study, cell differentiation was not as deeply evaluated as in other studies where the in vitro increase in UCB-HSC number was not accompanied by an evaluation of commitment status using additional antigens other than CD34 and CD38 [46] . HSC primitive phenotype characterization in humans is essentially based on CD34 (presence) and CD38 (absence) marker assessment, but many cells subsist within the CD38+ population with repopulating capability [59] [60] [61] . This shows that there are probably many more CD34+ cell subpopulations that have not been completely characterized to date, suggesting the need for other markers when evaluating primitive or progenitor status. Appealingly, different markers are used in BM clinical evaluation to define differentiation status. Recent results have shown a significant association between HSC c-kit expression and perivascular niches. Butler et al. showed that in cytokine-free co-cultures, endothelial cells stimulate the expansion of the CD34-, Flt3-, c-kit+, Lin-and Sca-1+ populations, retaining a higher repopulation capacity of BM in in vivo assays [62] . Other authors have shown that SCF deletion (c-kit ligand) in endothelial and perivascular stem cells or leptin receptor (+) cells dramatically affect the number of HSC [63] . Also, the c-kit+ population may further regulate its microenvironment by inducing osteoblast formation from MSC [64] . The latter may suggest a reciprocal positive effect of c-kit-bearing cells on niche maintenance and vice versa. We took advantage of this concept to consider the c-kit antigen as an alternative marker for in vitro primitive progenitor cell evaluation. Our results showed that the HM conditions promoted the maintenance of the CD34+c-kit+ population (92.4%) with a reduction in the more differentiated CD34+CD33+ (16%) population (Fig. 4.) . We also showed higher CD34 and c-kit MFI under HM conditions after 7 days' co-culture when compared with both cytokine conditions (HMC and HC; Fig. 6, Supplementary Table 2 ). This finding is very interesting since this population (CD34+c-kit+) has an important role in normal [65] and pathological hematopoiesis [66] , acute myocardial infarction [67] and vascular remodeling [68, 69] . We have detected an intermediate HLA-DR expression without significant changes between the cell populations and culture conditions analyzed (data not shown). Lymphoid antigens were not detected in the three systems assayed here, probably because of the culture period assayed. In fact, Gardner et al. have shown that lymphoid progenitor generation from CD34+ cells may require longer cultivation periods [70] and other studies have shown that the number of lymphoid progenitors in UCB is very low (0.02%) [71, 72] . Several reports have shown that BM-MSC increase CD34+ cell proliferation and short-term engraftment in recipient NOD/SCID mice [73] but the influence of BM-MSC on UCB-CD34+ multi-lineage capacity has not been shown by clonogenic assays. In particular, clonogenic assays are widely used as a test for assessing HSC in vitro differentiation capacity. Here we have observed (Fig. 7 and Fig. 8 ) that UCB-CD34+c-kit+ developed a greater number of CFU-GEMM under the HM conditions compared to the two culture conditions with cytokines. Interestingly, the absolute CFU-GEMM count increased in the HM condition by more than 3 times compared to the basal count. It is likely that contact with BM-MSC could regulate HSC self-renewal. This might have indicated that the CD34+c-kit phenotype corresponded to primitive progenitors and that they were regulated, at least partly, by direct contact with BM-MSC, as shown in our assays with BM-MSC supernatants (Fig. 9) . Taking all these results into consideration, one could argue that increased UCB-HSC proliferation may be more dependent on paracrine factors (cytokines), while increased CD34+c-kit+ cells and CFU-GEMM may be promoted by direct contact with BM-MSC. Once physical association between MSC and HSC has occurred, sufficient time must elapse for the various signals [74, 75] to be able to modulate HSC cell fate, retaining their original characteristics but allowing some proliferation to increase cell number. A co-culture system that increases the CD34+c-kit+ cell subpopulation, improving UCB-HSC "quality", would be also very useful for HSC stored for long periods on CB banks. These findings may optimize the use of CD34+c-kit+ cell subpopulation for patients with congenital or acquired aplasias, leukemia patients undergoing myeloablative therapy or patients with diseases not associated with the hematopoietic system, such as myocardial infarction or vascular disease. 
